Catalyst
Slingshot members are tracking this event:
FDA accepts IND for Advaxis' (ADXS) drug candidate, ADXS-503, a Phase 1/2 for the treatment of non-small cell lung cancer (NSCLC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADXS |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 30, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Adxs-503, Phase 1/2, Non-small Cell Lung Cancer
